The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC)
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …

Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for
platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) …

Introduction The efficacy and safety of atezolizumab versus the efficacy and safety of
docetaxel as second-or third-line treatment in patients with advanced NSCLC in the primary …

Immune checkpoint blockade has been a pivotal development in the management of
advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and …

The efficacy of immunotherapy varies widely among different gastrointestinal cancers.
Response to immune checkpoint inhibitors is shown to correlate with tumor mutation load …

Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with
solid tumours following the demonstration of the impressive clinical efficacy of anti …

Tumor mutational burden (TMB) is a new biomarker for prediction of response to PD-(L) 1
treatment. Comprehensive sequencing approaches (ie, whole exome and whole genome …